Market Overview

Omeros Up 18+% After Positive Results in MASP-3 Inhibitor OMS906 Study, Showed Sustained Ablation of APC Activity for ~16 Days; Preparing for Clinical Trials

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News FDA Movers

 

Related Articles (OMER)